Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (OlmetecŽ), launched in 2002 by Sankyo and now available in more than 20 countries around the world; the antiplatelet agent prasugrel (EfientŽ), launched in 2009 for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); and edoxaban (LixianaŽ), the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism (VTE). Daiichi Sankyo is based in Tokyo and today has 50 billion yen in capital. Source
No articles found.
Establishment Labs is a global medical technology company focused on improving pat...
Establishment Labs is a global medical technolo...
Genmab is a publicly traded, international biotechnology company specializing in t...
Genmab is a publicly traded, international biot...
At Achillion, we are driven to transform the lives of patients and families affect...
At Achillion, we are driven to transform the li...
Founded in 1996, PetMed Express is America's Largest Pet Pharmacy, delivering pres...
Founded in 1996, PetMed Express is America's La...
The Medicines Company is a biopharmaceutical company driven by an overriding purpo...
The Medicines Company is a biopharmaceutical co...
Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...
Forward Pharma A/S is a Danish biopharmaceutica...
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision med...
MyoKardia is a clinical-stage biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.